|
[1] VILSTRUP H, AMODIO P, BAJAJ J, et al. Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology, 2014, 60 (2) :715-735.
|
|
[2] MANCINI A, CAMPAGNA F, AMODIO P, et al. Gut∶Liver∶Brain axis:The microbial challenge in the hepatic encephalopathy[J].Food Funct, 2018, 9 (3) :1373-1388.
|
|
[3] ACHARYA C, BAJAJ JS. Current management of hepatic encephalopathy[J]. Am J Gastroenterol, 2018, 113 (11) :1600-1612.
|
|
[4] BAJAJ JS, RIDLON JM, HYLEMON PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302 (1) :g168-g175.
|
|
[5] BAJAJ JS, HYLEMON PB, RIDLON JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303 (6) :g675-g685.
|
|
[6] ZHANG Z, ZHAI H, GENG J, et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing[J]. Am J Gastroenterol, 2013, 108 (10) :1601-1611.
|
|
[7] BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol, 2014, 60 (5) :940-947.
|
|
[8] AHLUWALIA V, BETRAPALLY NS, HYLEMON PB, et al. Impaired gut-liver-brain axis in patients with cirrhosis[J]. Sci Rep, 2016, 6:26800.
|
|
[9] YILDIZ S, DOGAN I, DOGRUMAN-AL F, et al. Association of enteric protist blastocystis spp. and gut microbiota with hepatic encephalopathy[J]. J Gastrointestin Liver Dis, 2016, 25 (4) :489-497.
|
|
[10] CHEN Y, YANG F, LU H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology, 2011, 54 (2) :562-572.
|
|
[11] FELIPO V, URIOS A, MONTESINOS E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy[J]. Metab Brain Dis, 2012, 27 (1) :51-58.
|
|
[12] LU BJ, ZHAO YH, AN YT, et al. Research advances in gut microbiota in liver cirrhosis and related complications[J]. J Clin Hepatol, 2018, 34 (11) :2433-2437. (in Chinese) 鲁冰洁, 赵亚红, 安泳潼, 等.肠道微生物在肝硬化及相关并发症中的研究进展[J].临床肝胆病杂志, 2018, 34 (11) :2433-2437.
|
|
[13] HE ZJ, SONG HY. Research progress of the relationship between intestinal flora and cirrhosis[J]. Med Recapitulate, 2017, 23 (20) :3984-3988. (in Chinese) 何志钧, 宋怀宇.肠道菌群与肝硬化关系的研究进展[J].医学综述, 2017, 23 (20) :3984-3988.
|
|
[14] LYU XY, LI L. Clinical effect of rifaximin in treatment of complications associated with liver cirrhosis[J]. J Clin Hepatol, 2018, 34 (7) :1551-1554. (in Chinese) 吕新月, 李磊.利福昔明在肝硬化相关并发症中的应用[J].临床肝胆病杂志, 2018, 34 (7) :1551-1554.
|
|
[15] TREBICKA J, KRAG A, GANSWEID S, et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2011, 23 (12) :1218-1225.
|
|
[16] MORTENSEN C, KARLSEN S, GRONBAEK H, et al. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion[J]. Liver Int, 2013, 33 (9) :1309-1315.
|
|
[17] LYNCH SV, PEDERSEN O. The human intestinal microbiome in health and disease[J]. N Engl J Med, 2016, 375 (24) :2369-2379.
|
|
[18] QIN N, YANG F, LI A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513 (7516) :59-64.
|
|
[19] YANO JM, YU K, DONALDSON GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis[J]. Cell, 2015, 161 (2) :264-276.
|
|
[20] TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035-2044.
|
|
[21] RONNEMAA E, ZETHELIUS B, VESSBY B, et al. Serum fatty-acid composition and the risk of Alzheimer's disease:A longitudinal population-based study[J]. Eur J Clin Nutr, 2012, 66 (8) :885-890.
|
|
[22] LACHAR J, BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36 (4) :327-330.
|
|
[23] RIDLON JM, ALVES JM, HYLEMON PB, et al. Cirrhosis, bile acids and gut microbiota:Unraveling a complex relationship[J]. Gut Microbes, 2013, 4 (5) :382-387.
|
|
[24] RIGGIO O, MANNAIONI G, RIDOLA L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients:A study on the pathophysiology of hepatic encephalopathy[J].Am J Gastroenterol, 2010, 105 (6) :1374-1381.
|
|
[25] KONOPELSKI P, UFNAL M. Indoles-gut bacteria metabolites of tryptophan with pharmacotherapeutic potential[J]. Curr Drug Metab, 2018, 19 (10) :883-890.
|
|
[26] BAJAJ JS, GILLEVET PM, PATEL NR, et al. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy[J]. Metab Brain Dis, 2012, 27 (2) :205-215.
|
|
[27] LIU Q, DUAN ZP, HA DK, et al. Synbiotic modulation of gut flora:Effect on minimal hepatic encephalopathy in patients with cirrhosis[J]. Hepatology, 2004, 39 (5) :1441-1449.
|
|
[28] BAJAJ JS, HEUMAN DM, SANYAL AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy[J]. PLo S One, 2013, 8 (4) :e60042.
|
|
[29] LUNIA MK, SHARMA BC, SHARMA P, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis:A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.
|
|
[30] BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Randomised clinical trial:Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39 (10) :1113-1125.
|
|
[31] ZUO Z, FAN H, TANG XD, et al. Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients[J]. Exp Ther Med, 2017, 14 (5) :4887-4895.
|
|
[32] FULLER R. Probiotics in man and animal[J]. J Appl Bacteriol, 1989, 66 (5) :36-378.
|
|
[33] MCGEE RG, BAKENS A, WILEY K, et al. Probiotics for patients with hepatic encephalopathy[J]. Cochrane Database Syst Rev, 2011, 11:cd008716.
|
|
[34] SHUKLA S, SHUKLA A, MEHBOOB S, et al. Meta-analysis:The effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2011, 33 (6) :662-671.
|
|
[35] HOLTE K, KRAG A, GLUUD LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy[J]. Hepatol Res, 2012, 42 (10) :1008-1015.
|
|
[36] XU J, MA R, CHEN LF, et al. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis:An updated meta-analysis of six randomized controlled trials[J].Hepatobiliary Pancreat Dis Int, 2014, 13 (4) :354-360.
|
|
[37] ZHAO LN, YU T, LAN SY, et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy:An update meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2015, 39 (6) :674-682.
|
|
[38] SAAB S, SURAWEERA D, AU J, et al. Probiotics are helpful in hepatic encephalopathy:A meta-analysis of randomized trials[J]. Liver Int, 2016, 36 (7) :986-993.
|
|
[39] DALAL R, MCGEE RG, RIORDAN SM, et al. Probiotics for people with hepatic encephalopathy[J]. Cochrane Database Syst Rev, 2017, 2:cd008716.
|
|
[40] CAO Q, YU CB, YANG SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy:A meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17 (1) :9-16.
|
|
[41] VIRAMONTES HD, AVERY A, STOW R. The Effects of probiotics and symbiotics on risk factors for hepatic encephalopathy:A systematic review[J]. J Clin Gastroenterol, 2017, 51 (4) :312-323.
|
|
[42] MALAGUARNERA G, GIORDANO M, NUNNARI G, et al. Gut microbiota in alcoholic liver disease:Pathogenetic role and therapeutic perspectives[J]. World J Gastroenterol, 2014, 20 (44) :16639-16648.
|
|
[43] MALAGUARNERA M, GARGANTE MP, MALAGUARNERA G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy[J]. Eur J Gastroenterol Hepatol, 2010, 22 (2) :199-206.
|
|
[44] CHEN W, YANG T, LIU WL. The clinical application of fecal microbiota transplantation[J/CD]. Chin J Transplant:Electronic Edition, 2018, 12 (1) :42-48. (in Chinese) 陈卫, 杨涛, 刘玮丽.粪菌移植的临床应用[J/CD].中华移植杂志:电子版, 2018, 12 (1) :42-48.
|
|
[45] KAO D, ROACH B, PARK H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J].Hepatology, 2016, 63 (1) :339-340.
|
|
[46] BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J]. Hepatology, 2017, 66 (6) :1727-1738.
|
|
[47] SARANGI AN, GOEL A, SINGH A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration[J]. BMC Gastroenterol, 2017, 17 (1) :125.
|
|
[48] KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2017, 46 (9) :845-855.
|
|
[49] KALAMBOKIS GN, MOUZAKI A, RODI M, et al. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia[J]. Liver Int, 2012, 32 (3) :467-475.
|
|
[50] BAJAJ JS. Review article:Potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43 (Suppl 1) :11-26.
|
|
[51] BROWN EL, XUE Q, JIANG ZD, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles[J]. Antimicrob Agents Chemother, 2010, 54 (1) :388-396.
|
|
[52] RAI R, AHUJA CK, AGRAWAL S, et al. Reversal of lowgrade cerebral edema after lactulose/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy[J].Clin Transl Gastroenterol, 2015, 6:e111.
|
|
[53] TSAI CF, CHEN MH, WANG YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study[J]. Gastroenterology, 2017, 152 (1) :134-141.
|
|
[54] ACHARYA C, BETRAPALLY NS, GILLEVET PM, et al. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2017, 45 (2) :319-331.
|
DownLoad: